CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $54.74, moving -2.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%.

CRISPR is one of the most revolutionary technologies of the modern era, and now it's being used to bring back long-lost genes ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of more ...

Study finds CRISPR/Cas gene editing causes “chromatin fatigue” – another surprise mechanism by which it can produce unwanted ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Inside cells, DNA twists and coils itself into a variety of different secondary structures—including i-motifs (iMs) and ...

The world's first treatment that uses CRISPR gene-editing technology has been approved. Exa-cel, also known by its brand name Casgevy, received its first regulatory approval on Nov. 16, 2023 from the ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...